Meetings with SI's and instos, now presentation. I think we all know what's next. question is at what price and will there be a spp? All IMO of course.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling